Peptide Graded

Icatibant

Is Icatibant safe?

Trial and label safety data

AStrong human evidenceFDA approvedas of 2026-10-26

Almost every patient gets an injection-site reaction. These include redness, swelling, warmth, itching or pain at the site. They usually fade within hours. Other reported effects include fever, raised liver enzymes, dizziness and rash. Bradykinin also protects the heart. So the label advises caution in patients with acute ischaemic heart disease or stroke. The trials did not show a heart signal. After treating a laryngeal attack, patients are told to seek emergency care whatever the response. 12

Read the full Icatibant page

More on Icatibant

Citations

  1. Lumry 2011, Annals of Allergy, Asthma and Immunology: randomised placebo-controlled trial of icatibant for acute attacks of hereditary angioedema (FAST-3) doi.org
  2. NDC List: Firazyr (icatibant injection) label ndclist.com

Reference information only, not medical advice. Drawn from the Icatibant article, fact-checked against the cited sources. No dosing anywhere on this site.